arrow
M

Michael S. Seaman

Beth Israel Deaconess Medical Center
H指数:104
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies

每年一次细胞疗法用于持续且剂量可调的单克隆抗体递送

2026-10-020
OAAI
Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial

在HIV感染者男性接受分析性治疗中断期间的中和抗体:RIO试验II期随机对照试验的次要和探索性结局

2026-09-150
OAAI
Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design

通过两步机制诱导广谱中和HIV抗体为疫苗设计提供信息

Science
IF45.8
2026-05-070
PRE
B lymphocyte protein factories produced by hematopoietic stem cell gene editing

造血干细胞基因编辑产生的B淋巴细胞蛋白质工厂

Science
IF45.8
2026-04-160
PRE
Mechanisms of early-life immunity associated with induction of heterologous HIV-1 neutralizing antibodies
2025-11-010
PRE
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans

疫苗诱导异源HIV-1中和抗体B细胞谱系在人类中

Cell
IF42.5
2025-11-010
OAAI
Hydrogel formulations for sustained-release of broadly neutralizing antibodies

长效广谱中和抗体的水凝胶制剂

2025-10-310
PRE
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy

HIV-1精英中和者队列的表征分析揭示了一种靶向CD4bs的广谱中和抗体,可用于HIV-1的预防和治疗

2025-10-060
OA
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning

通过双特异性抗体介导的预定位增强的广谱抗体介导的HIV-1中和作用

2025-05-180
OA
A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV

一项全面的工程策略提高了针对HIV的近全中和抗体的效力和可制造性。

2025-05-140
OA
Computationally designed proteins mimic antibody immune evasion in viral evolution

计算设计的蛋白质模拟病毒进化中的抗体免疫逃逸

Immunity
IF26.3
2025-05-080
OA
Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques
2024-11-270
OAAI
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial
2024-09-121
OA
Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

种系靶向HIV疫苗可诱导CD4结合位点的中和抗体

2024-08-301
PRE
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
2024-05-230
OAAI
Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains
2024-05-210
OAAI
Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques
2024-03-272
PRE